Biotech Daily, Daily news on ASX-listed biotechnology companies | Biotech Daily Home

Time 2021-01-03 09:04:26

Web Name: Biotech Daily, Daily news on ASX-listed biotechnology companies | Biotech Daily Home

WebSite: http://www.biotechdaily.com.au

ID:155061

Keywords:

news,on,Biotech,

Description:

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1600 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management. Download subscription form here The Biotech Daily Top-40 Index (BDI-40) fully recovered from the Sars-Cov-2 pandemic in November, up $2,303 million to an all-time high of $18,049 million. The benchmark S P ASX200 was up 9.95 percent in November and down 4.8 percent for the year to November 30. The BDI-40 (which does not include the three Big Caps of Cochlear, CSL and Resmed) climbed 19.5 percent for the 12 months. The collective market capitalization of the Big Caps was up 1.95 percent in November (and 9.7 percent for the year) to $190,744 million, just $594 million (0.3%) below the all-time high of $191,338 million at the end of February, just before the pandemic took hold of the markets. Cochlear and Resmed both hit record highs, up 1.15 percent to $14,491 million and 2.0 percent to $40,953 million, respectively, with CSL also up 2.0 percent to $135,300 million. The Nasdaq Biotechnology Index was up 11.1 percent in November and 21.3 percent for the year to November 30, 2020. In possibly the BDI-40 s best month on record, 31 companies were up, two by more than 100 percent and 12 by more than 20 percent, while just eight fell and one was unchanged. Telix was the best, on a series of acquisitions and partnerships, up $563 million or 132.5 percent to $988 million, last night, and joining the $1 billion club in trading earlier today. Imugene was up $292 million or 118.2 percent, partly on impressive cancer results the company claimed were statistically significant but did not conform to conventional methodology. Impedimed almost doubled in value, up 97.8 percent to $178 million, followed by Kazia (74.0%), Universal Biosensors (43.9%) Mesoblast (32.0%), Immutep (29.7%), Nanosonics (26.9%), Compumedics (26.0%), Oncosil (23.3%), Medical Developments (21.1%) and Orthocell (20.0%). Pro Medicus led the falls, slipping 10.3 percent or $353 million from last month s record high to $3,078 million, followed by Starpharma (10.1%), Patrys (8.8%), Genetic Signatures (5.9%), Clinuvel (5.5%), Cynata (3.1%), Avita (2.0%) and Dimerix (1.96%). Outside the Top 40, Imagion was up 115 percent for the month but 1,333 percent for the year to $129 million. For the 12 months to November 30, Race Oncology was up 1,235 percent to $267 million, followed by Rhythm Bio (1,155.5%), Emvision (471.4%), Recce (424.3%), Noxopharm (226.2%), Micro-X (200%), Mach7 (184.8%) and 4D (115.2%). Cannabis Corner recovered 25.6 percent to a collective $1,450 million, down 8.3 percent for the year to November 30. On the Nasdaq, Eyepoint (Psivida) was up 49.3 percent to $106 million, Queensland s Protagonist rose 26.8 percent to $1,258 million and Redhill (with Australian assets) edged up 2.0 percent to $454 million.Click here for Biotech Daily's archive Biotech Daily Top 40 With Market Capitalization At November 30, 2020 * Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Cochlear Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. These holdings are liable to change: https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.

TAGS:news on Biotech 

<<< Thank you for your visit >>>

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as developments in government policy and regulation. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

Hot Websites